Such a pro-tolerogenic shift is associated with NEDA in MS patients (158); higher levels of the NRF2 target gene NAD(P)H quinone dehydrogenase 1 (NQO1) was also associated with NEDA status after 1 year of DMF treatment (151). This evidence concerns the gene NQO1 and myeloid sarcoma.